Literature DB >> 7633411

Hyperhomocysteinemia in premature arterial disease: examination of cystathionine beta-synthase alleles at the molecular level.

V Kozich1, E Kraus, R de Franchis, B Fowler, G H Boers, I Graham, J P Kraus.   

Abstract

Hyperhomocysteinemia occurs in approximately 30% of the patients with premature occlusive arterial disease (POAD). Some of these exhibit significantly reduced fibroblast cystathionine beta-synthase (CBS) activities, suggesting that they may be heterozygous for CBS deficiency. To test this possibility, we studied cDNA derived from four well characterized patients with POAD, exhibiting hyperhomocysteinemia and reduced CBS activities, from four normal controls, and from four obligatory heterozygotes for CBS deficiency. Lysates of individual colonies of E.coli, containing full-length PCR-amplification products in the expression vector, pKK388.1, were tested for CBS activity. cDNA from at least seven of the eight possible independent POAD alleles encoded catalytically active, stable CBS which exhibited normal response to both PLP and AdoMet. The sequences of all 3'-untranslated regions of all seven isolated POAD alleles were identical to the normal, 'wild-type' CBS sequences. The results of the expression studies were confirmed for one POAD patient by determining the full-length cDNA sequences for both alleles; these were entirely normal over the complete length of the cDNA. In contrast, the screening method correctly distinguished mutant from normal alleles in all four obligatory heterozygotes studied. We conclude that CBS mRNAs from POAD individuals are free from inactivating mutations, including all 33 previously identified in heterozygous carriers and homocystinuric patients.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7633411     DOI: 10.1093/hmg/4.4.623

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  8 in total

1.  Is the common 844ins68 polymorphism in the cystathionine beta-synthase gene associated with atherosclerosis?

Authors:  M Orendác; B Musková; E Richterová; J Zvárová; M Stefek; E Zaykova; J P Kraus; J Stríbrný; J Hyánek; V Kozich
Journal:  J Inherit Metab Dis       Date:  1999-06       Impact factor: 4.982

Review 2.  Hyperhomocysteinaemia and associated disease.

Authors:  R C Bakker; D P Brandjes
Journal:  Pharm World Sci       Date:  1997-06

Review 3.  Assessment of homocysteine status.

Authors:  H Refsum; T Fiskerstrand; A B Guttormsen; P M Ueland
Journal:  J Inherit Metab Dis       Date:  1997-06       Impact factor: 4.982

Review 4.  Disorders of homocysteine metabolism.

Authors:  B Fowler
Journal:  J Inherit Metab Dis       Date:  1997-06       Impact factor: 4.982

Review 5.  Nutritional ecogenetics: homocysteine-related arteriosclerotic vascular disease, neural tube defects, and folic acid.

Authors:  A G Motulsky
Journal:  Am J Hum Genet       Date:  1996-01       Impact factor: 11.025

Review 6.  Homocystinuria: what about mild hyperhomocysteinaemia?

Authors:  M van den Berg; G H Boers
Journal:  Postgrad Med J       Date:  1996-09       Impact factor: 2.401

7.  Comparative effects of acute-methionine loading on the plasma sulfur-amino acids in NAC-supplemented HIV+ patients and healthy controls.

Authors:  Roberto Carlos Burini; Maria Doroteia Borges-Santos; Fernando Moreto; Yong- Ming Yu
Journal:  Amino Acids       Date:  2018-02-01       Impact factor: 3.520

8.  Molecular genetic analysis in mild hyperhomocysteinemia: a common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease.

Authors:  L A Kluijtmans; L P van den Heuvel; G H Boers; P Frosst; E M Stevens; B A van Oost; M den Heijer; F J Trijbels; R Rozen; H J Blom
Journal:  Am J Hum Genet       Date:  1996-01       Impact factor: 11.025

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.